Press Releases Year None201920182017 July 8, 2019 Prevail Therapeutics Receives U.S. FDA Fast Track Designation for PR001 for the Treatment of Parkinson’s Disease Patients with a GBA1 Mutation June 19, 2019 Prevail Therapeutics Announces Pricing of Initial Public Offering June 4, 2019 Prevail Therapeutics Announces IND Active for Phase 1/2 Trial of its Gene Therapy PR001 to Treat Parkinson’s Disease Patients with GBA1 Mutations May 16, 2019 Prevail Therapeutics Announces Executive Team Promotion and Appointments to Board of Directors March 27, 2019 Prevail Therapeutics Secures $50 Million in Series B Financing to Advance Pipeline of Gene Therapies for Neurodegenerative Diseases Pagination First page « first Previous page ‹ previous Page 1 Current page 2 Displaying 11 - 15 of 15
